Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), setting up a potential label expansion for the drug as a first-line option ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in the ...

The last time I spoke about Incyte (INCY) it was with respect to a Seeking Alpha article entitled "Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio." With respect to ...

Incyte (INCY) shares soared 5.5% in the last trading session to close at $102.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Jan 5 (Reuters) - Incyte (INCY.O), opens new tab said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their disease worsening in a late-stage ...

If you are wondering whether Incyte at around $100 a share is still good value or if the easy gains are behind it, you are not alone. This is exactly the question we are going to unpack. The stock is ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma - Phase 3 frontMIND trial evaluating the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.